Abstract: AIM: To observe the effect of sibutramine on the obesity with metabolic disorder of blood glucose and lipid.METHODS: Subjects with BMI (body mass index) over 25 kg·m^-2 were selected.The observedin-dexes included the weight, waist and hip measurements, abdomen measurement, blood lipid, blood glucose levels fasting and after a standard test meal (FBS and 2PBS), bloodinsulin, and glcosylated haemoglobine (HbAIC) level, before and after taking sibutramine.RESULTS: After taking sibutramine, it was significantly improved (P<0.01) in the abdomen measurement, lipid rate and lipid mass in the 41 patients with obesity.The FBS, 2PBS, weight, and abdominal measurement decreasedin 18 patients with metabolic disorder of blood glucose (P<0.01).The bloodinsulin and HbAIC had no significant changes, but triglycerides (TG), cholesterol (CHO), high-density lipoprotein (HDL), and low-density li-porotein (LDL) were improved.CONCLUSION: Sibu-tramine can decrease weight, improve the disorders of blood glucose and lipid, and decrease cardio-vascular dis-ease risk factors in the patients with metabolic disorder of blood gucose and lipid.

Key words: sibutramine, obesity, metabolic disor-ders of blood glucose and lipid